Sign In
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- US Share Prices
- Stock Tips
- Share Chat
- FX
- News & RNS
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Faron Pharmaceuticals Share News (FARN)
FARN Share
Price
FARN Share
News
FARN Share
Chat
FARN Share
Trades15
FARN
Live RNS
FARN Share
Charts
FARN Level 2
Console
FARN Live
Share Price
FARN Broker
Ratings
FARN Directors
Deals
FARN Financial
Diary
FARN
Fundamentals
FARN Short
Positions
FARN
Media
FARN Company
Research
FARN Company
Timeline
Share Price Information for Faron Pharmaceuticals (FARN)
Last checked at -
Last checked at 
Intraday Faron Pharmaceuticals Share Chart
Faron Pharmaceuticals Notes Study Supporting Clevegen Programme
LONDON (Alliance News) - Faron Pharmaceuticals Oy on Monday said an article published in the Journal of Immunology has outlined the functional role of the company's Clever-1 treatment, part of its Clevegen cancer immunotherapy antibody programme.
Faron, which floated in London earlier this month, said the data published in the study supported Clever-1 as an immuosuppresive molecule and supports the use of Clevegen as an immunotherapy product.
"We are working hard to advance our Clevegen programme, as announced recently, towards clinical use as a new onco-immunological alternative," said Faron Chief Executive Markku Jalkanen.
Shares in Faron were trading flat at 275.00 pence on Monday.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Latest FARN News
- IN BRIEF: Faron Pharmaceuticals shares up as presents data on Bexmab
10 Dec 2024 - Faron Pharmaceuticals reports regulatory progress in the UK
2 Dec 2024 - Faron announces promising MDS trial results
27 Nov 2024 - Faron announces promising findings from blood cancer drug trial
27 Nov 2024 - Faron Pharmaceuticals files new patent for Clever-1
11 Nov 2024 - Faron Pharmaceuticals candidate gets FDA fast track designation
27 Aug 2024 - Faron Pharma shares surge as US FDA grants fast track designation
27 Aug 2024 - UK earnings, trading statements calendar - next 7 days
20 Aug 2024
Related News
IN BRIEF: Faron Pharmaceuticals fined EUR30,000 by Nasdaq Helsinki
Faron Pharmaceuticals Ltd - Turku, Finland-based cancer drug developer - Says the Disciplinary Committee of Nasdaq Helsinki Ltd has imposed an EUR30,0...
WINNERS & LOSERS: James Cropper sees earnings up; Block sells stake
(Alliance News) - The following are the leading risers and fallers among London Main Market small-cap and AIM stocks on Tuesday.
Faron Pharmaceuticals News
IN BRIEF: Faron Pharmaceuticals shares up as presents data on Bexmab
Faron Pharmaceuticals PLC on Tuesday - Turku, Finland-based developer of cancer immunotherapies - Presents full analysis of positive phase 2 interim d...
Faron Pharmaceuticals reports regulatory progress in the UK
(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals announced significant regulatory progress in the UK for its lead ass...
Faron announces promising MDS trial results
(Sharecast News) - Faron Pharmaceuticals announced promising interim phase two results from its 'BEXMAB' trial on Wednesday, targeting relapsed or ref...
Faron announces promising findings from blood cancer drug trial
(Alliance News) - Faron Pharmaceuticals Ltd on Wednesday reported positive data from an ongoing trial on patients receiving a new treatment for a rare...
Faron Pharmaceuticals files new patent for Clever-1
(Sharecast News) - Faron Pharmaceuticals, a clinical-stage biopharmaceutical company specialising in immunotherapies for cancer and inflammatory disea...
Faron Pharmaceuticals candidate gets FDA fast track designation
(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals announced on Tuesday that its lead candidate, bexmarilimab, has been...
Faron Pharma shares surge as US FDA grants fast track designation
(Alliance News) - Faron Pharmaceuticals Ltd on Tuesday said its loss widened in the first half of 2024, as the company successfully advanced the devel...
Follow the stocks
